<?xml version='1.0' encoding='utf-8'?>
<document id="24530864"><sentence text="Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration."><entity charOffset="70-80" id="DDI-PubMed.24530864.s1.e0" text="rifampicin" /></sentence><sentence text="The induction of cytochrome P450 enzymes (CYPs) is an important source of drug-drug interaction (DDI) and can result in pronounced changes in pharmacokinetics (PK)" /><sentence text=" Rifampicin (RIF) is a potent inducer of CYP3A4 and also acts as a competitive inhibitor which can partially mask the induction"><entity charOffset="1-11" id="DDI-PubMed.24530864.s3.e0" text="Rifampicin" /><entity charOffset="13-16" id="DDI-PubMed.24530864.s3.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.24530864.s3.e0" e2="DDI-PubMed.24530864.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24530864.s3.e0" e2="DDI-PubMed.24530864.s3.e1" /></sentence><sentence text=" The objective of this study was to determine a clinical DDI study design for RIF resulting in maximum CYP3A4 induction"><entity charOffset="78-80" id="DDI-PubMed.24530864.s4.e0" text="RIF" /></sentence><sentence text=" A physiologically based pharmacokinetic (PBPK) model was developed to project the dynamics and magnitude of CYP3A4 induction in vivo from in vitro data generated with primary human hepatocytes" /><sentence text=" The interaction model included both inductive and inhibitory effects of RIF on CYP3A4 in gut and liver and accounting for the observed RIF auto-induction"><entity charOffset="73-75" id="DDI-PubMed.24530864.s6.e0" text="RIF" /><entity charOffset="136-138" id="DDI-PubMed.24530864.s6.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.24530864.s6.e0" e2="DDI-PubMed.24530864.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24530864.s6.e0" e2="DDI-PubMed.24530864.s6.e1" /></sentence><sentence text=" The model has been verified for 4 CYP3A4 substrates: midazolam, triazolam, alfentanil and nifedipine using plasma concentration data from 20 clinical study designs with intravenous (n=7) and oral (n=13) administrations"><entity charOffset="54-63" id="DDI-PubMed.24530864.s7.e0" text="midazolam" /><entity charOffset="65-74" id="DDI-PubMed.24530864.s7.e1" text="triazolam" /><entity charOffset="76-86" id="DDI-PubMed.24530864.s7.e2" text="alfentanil" /><entity charOffset="91-101" id="DDI-PubMed.24530864.s7.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e0" e2="DDI-PubMed.24530864.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e0" e2="DDI-PubMed.24530864.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e0" e2="DDI-PubMed.24530864.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e0" e2="DDI-PubMed.24530864.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e1" e2="DDI-PubMed.24530864.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e1" e2="DDI-PubMed.24530864.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e1" e2="DDI-PubMed.24530864.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e2" e2="DDI-PubMed.24530864.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24530864.s7.e2" e2="DDI-PubMed.24530864.s7.e3" /></sentence><sentence text=" Finally, the influence of the time between RIF and substrate administration was explored for the interaction between midazolam and RIF"><entity charOffset="44-53" id="DDI-PubMed.24530864.s8.e0" text="RIF" /><entity charOffset="132-141" id="DDI-PubMed.24530864.s8.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.24530864.s8.e0" e2="DDI-PubMed.24530864.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24530864.s8.e0" e2="DDI-PubMed.24530864.s8.e1" /></sentence><sentence text=" The model integrating in vitro induction parameters correctly predicted intravenous induction but underestimated oral induction with 30% of simulated concentrations more than 2-fold higher than of observed data" /><sentence text=" The use of a 1" /><sentence text="6-fold higher value for the maximum induction effect (Emax) improved significantly the accuracy and precision of oral induction with 82% of simulated concentrations and all predicted PK parameters within 2-fold of observed data" /><sentence text=" Our simulations suggested that a concomitant administration of RIF and midazolam resulted in significant competitive inhibition limited to intestinal enzyme"><entity charOffset="72-81" id="DDI-PubMed.24530864.s12.e0" text="midazolam" /><entity charOffset="64-72" id="DDI-PubMed.24530864.s12.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.24530864.s12.e1" e2="DDI-PubMed.24530864.s12.e1" /><pair ddi="false" e1="DDI-PubMed.24530864.s12.e1" e2="DDI-PubMed.24530864.s12.e0" /></sentence><sentence text=" Accordingly, a maximum induction effect could be achieved with a RIF pretreatment of 600 mg/day during 5 days and a substrate administration at least 2 h after the last RIF dose"><entity charOffset="66-68" id="DDI-PubMed.24530864.s13.e0" text="RIF" /><entity charOffset="170-172" id="DDI-PubMed.24530864.s13.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.24530864.s13.e0" e2="DDI-PubMed.24530864.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24530864.s13.e0" e2="DDI-PubMed.24530864.s13.e1" /></sentence><sentence text=" A period of 2 weeks after RIF removal was found sufficient to allow return to baseline levels of enzyme"><entity charOffset="27-29" id="DDI-PubMed.24530864.s14.e0" text="RIF" /></sentence><sentence text="" /></document>